Pain-pill giant Purdue Pharma LP will stop promoting the opioid drugs to doctors, the retreat after years of criticism the company’ s aggressive sales initiatives helped lay the foundation of the Oughout. S. addiction crisis.
The company informed employees this week that it would reduce its sales force by more than half, in order to 200 workers. It plans to deliver a letter Monday to physicians saying that its salespeople will no longer get to their clinics to talk about the company’ s pain products.
“ We now have restructured and significantly reduced the commercial operation and will no longer be marketing opioids to prescribers, ” the organization said in a statement. Instead, any kind of questions doctors have will be guided to the Stamford, Connecticut-based company’ s medical affairs department.
OxyContin, approved in 1995, is the closely held company’ s biggest-selling drug, though product sales of the pain pill have dropped in recent years amid competition from generics. It generated $1. 8 billion dollars in 2017, down from $2. 8 billion five years previously, according to data compiled by Symphony Wellness Solutions. It also sells the painkiller Hysingla.
Purdue is credited along with helping develop many modern strategies of aggressive pharmaceutical promotion. The efforts to push OxyContin included OxyContin music, fishing caps and stuffed plush toys. Recently, it has positioned itself as an suggest for fighting the opioid dependancy crisis, as overdoses from prescription medications claim thousands of American lives every year.
Purdue and other opioid manufacturers and distributors face dozens of legal cases in which they’ re accused of making a public-health crisis through their own marketing of the painkillers. Purdue officials confirmed within November that they are in settlement discussions with a group of state attorneys common and trying to come up with a global quality of the government opioid claims.
More than 60, 000 individuals died from drug overdoses within 2016, and there was a fivefold increase in overdose deaths involving artificial opioids — from 3, 105 in 2013 to about twenty, 000 in 2016, according to the Centers for Disease Manage . The addiction epidemic price the American economy $504 billion dollars in 2015, the equivalent of 2 . 6 percent of the U. S. major domestic product that year, based on a report by the Council of Economic Agents.
About 200 leftover Purdue salespeople will focus on marketing the company’ s opioid caused constipation drug, Symproic. The medication launched last year in partnership with Shionogi & Co.